83 FR 33942 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 138 (July 18, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 138 (July 18, 2018)
| Page Range | 33942-33943 | |
| FR Document | 2018-15280 |
[Federal Register Volume 83, Number 138 (Wednesday, July 18, 2018)] [Notices] [Pages 33942-33943] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-15280] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [[Page 33943]] Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Sleep Apnea Treatment With Positive Airway Pressure for Prevention of Diabetes Mellitus. Date: July 27, 2018. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895, rushingp@extra.niddk.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Bariatric Surgery- Related Applications. Date: July 30, 2018. Time: 2:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895, rushingp@extra.niddk.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Type 1 Diabetes Small Business Applications. Date: August 6, 2018. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ryan G. Morris, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7015, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301- 594-4721, ryan.morris@nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA-DK-17-035 Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3). Date: August 7, 2018. Time: 11:30 a.m. to 3:30 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301- 594-2242, jerkinsa@niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity Research. Date: August 8, 2018. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 594-8898, barnardm@extra.niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA-DK-17-030 Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/ R44). Date: August 8, 2018. Time: 12:30 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301- 594-2242, jerkinsa@niddk.nih.gov. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK-R01 Telephone Review. Date: August 10, 2018. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Xiaodu Guo, MD, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7023, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-4719, guox@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: July 12, 2018. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy/ [FR Doc. 2018-15280 Filed 7-17-18; 8:45 am] BILLING CODE 4140-01-P
![33942 Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices
national security. The changes are as Advanced Research and Development • Division of Management Finance and
follows. Authority (BARDA), established in Human Capital (ANC1)
I. Under AN.10 Organization, delete April 2007 in response to the Pandemic • Division of Emergency Management
all of the components and replace with and All-Hazards Preparedness Act of and Medical Operations (ANC2)
the following: 2006, serves preparedness and response • Division of Resource Management
A. Immediate Office of the Assistant roles to provide medical (ANC3)
Secretary for Preparedness and countermeasures (MCM) in order to D. Deputy Assistant Secretary
Response (ANA) mitigate the medical consequences of Incident Command and Control (ANG):
B. Office of Biomedical Advanced chemical, biological, radiological, and The Deputy Assistant Secretary (DAS/
Research and Development Authority nuclear (CBRN) threats and agents and ICC) is responsible for the policy
(ANB) emerging infectious diseases, including development, planning analysis,
C. Office of the Principal Deputy pandemic influenza. BARDA executes requirements and strategic planning.
Assistant Secretary (ANC) this mission by facilitating research, DAS/ICC manages and operates the HHS
D. Office of the Deputy Assistant development, innovation, and Secretary’s Operation Center (SOC),
Secretary Incident Command and acquisition of MCM and expanding intelligence, security, information
Control (ANG) domestic manufacturing infrastructure management and is also responsible for
II. Delete AN.20 Functions, in its and surge capacity of these MCM. the HHS Continuity of Operations
entirety and replace with the following: BARDA is headed by a Deputy (COOP) and the development of the
Section AR.20 Functions. Assistant Secretary, and includes the ASPR COOP Plan. The Office of the
A. Immediate Office of the Assistant following components: Assistant Secretary Incident Command
Secretary for Preparedness and • Division of Influenza (ANB1) and Control (DAS/ICC) is headed by the
Response: The Immediate Office of the • Division of Emerging Infectious Deputy Assistant Secretary Incident
Assistant Secretary for Preparedness Diseases (ANB2) Command and Control, and includes the
and Response (IO/ASPR) is headed by • Division of Chemical, Biological, following components:
the Assistant Secretary, who provides Radiological and Nuclear Threats • Division of Security Intelligence and
leadership and executive and strategic (ANB3) Information Management
direction for the ASPR organization. • Division of Strategic Science and • Division of Strategy, Policy, Planning
The Assistant Secretary is the principal Technology (ANB4) and Requirements
advisor to the Secretary on all matters • Division of Regulatory and Quality III. Delegations of Authority. All
related to Federal public health and Affairs (ANB5) delegations and redelegations of
medical preparedness and response for • Division of Research, Innovation and authority made to officials and
public health emergencies. The Ventures (ANB6) employees of affected organizational
Assistant Secretary is responsible for C. Office of the Principal Deputy components will continue in them or
carrying out ASPR’s mission and Assistant Secretary (ANC). The Office of their successors pending further
implementing the functions of ASPR. the Principal Deputy Assistant Secretary redelegation, provided they are
The IO/ASPR (1) ensures development (OPDAS) is responsible for providing a consistent with this reorganization.
and maintenance of liaison well-integrated infrastructure that
relationships with HHS operating and supports the Department’s capabilities Alex M. Azar II,
staff divisions and represents HHS at to prevent, prepare for, respond to and Secretary.
interagency meetings, as required; (2) recover from natural public health and [FR Doc. 2018–15310 Filed 7–17–18; 8:45 am]
establishes and maintains effective medical threats and emergencies. BILLING CODE P
communications and outreach guidance OPDAS leads the preparedness and
and support for all external response activities required to
communications, including legislative coordinate public health and healthcare DEPARTMENT OF HEALTH AND
and executive branch questions and response systems and activities with HUMAN SERVICES
inquiries, and serves as the principal relevant federal, state, tribal, territorial,
advisor to the ASPR on all legislative local, and international communities National Institutes of Health
strategies to fulfill the Office of the under the National Response National Institute of Diabetes and
ASPR and the HHS mission under Framework and Emergency Support Digestive and Kidney Diseases; Notice
section 2811 and other relevant sections Annexes #8, #6 and #14. OPDAS is of Closed Meetings
of the Public Health Service Act, as responsible for the execution of
amended; (3) oversees advanced business management operations and Pursuant to section 10(d) of the
research, development and procurement managing coordination. OPDAS Federal Advisory Committee Act, as
of qualified countermeasures, security provides for the facility, logistics, amended, notice is hereby given of the
countermeasures and qualified information technology and following meetings.
pandemic or epidemic products; (4) infrastructure support services The meetings will be closed to the
coordinate with relevant federal officials necessary to maintain day-to-day public in accordance with the
to ensure integration of federal operations of ASPR, including functions provisions set forth in sections
preparedness and response activities for of Human Resources, Organization and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
public health emergencies; (5) manages Employee Development, Ethics, United as amended. The grant applications and
correspondence control for the Assistant States Public Health Service (USPHS) the discussions could disclose
amozie on DSK3GDR082PROD with NOTICES1
Secretary; and (6) coordinates the liaison, acquisitions management, confidential trade secrets or commercial
strategic and operational activities for contracts, grants, and all financial property such as patentable material,
public health preparedness response planning and analysis. and personal information concerning
and recovery. The Office of the Principal Deputy individuals associated with the grant
B. Office of Biomedical Advance Assistant Secretary is headed by the applications, the disclosure of which
Research and Development Authority Principal Deputy Assistant Secretary, would constitute a clearly unwarranted
(ANB). The Office of Biomedical and includes the following components: invasion of personal privacy.
VerDate Sep<11>2014 19:19 Jul 17, 2018 Jkt 244001 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 E:\FR\FM\18JYN1.SGM 18JYN1](https://thefederalregister.org/doc/83_FR_34080/page/1.svg)
![Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices 33943
Name of Committee: National Institute of Boulevard, Bethesda, MD 20892 (Telephone Dated: July 12, 2018.
Diabetes and Digestive and Kidney Diseases Conference Call). Ronald J. Livingston, Jr.,
Special Emphasis Panel; Sleep Apnea Contact Person: Ann A. Jerkins, Ph.D.,
Treatment With Positive Airway Pressure for Program Analyst, Office of Federal Advisory
Scientific Review Officer, Review Branch,
Prevention of Diabetes Mellitus. Committee Policy/
DEA, NIDDK, National Institutes of Health,
Date: July 27, 2018. Room 7119, 6707 Democracy Boulevard, [FR Doc. 2018–15280 Filed 7–17–18; 8:45 am]
Time: 1:00 p.m. to 2:00 p.m. Bethesda, MD 20892–5452, 301–594–2242, BILLING CODE 4140–01–P
Agenda: To review and evaluate grant
jerkinsa@niddk.nih.gov.
applications.
Place: National Institutes of Health, Two Name of Committee: National Institute of
Democracy Plaza, 6707 Democracy Diabetes and Digestive and Kidney Diseases DEPARTMENT OF HEALTH AND
Boulevard, Bethesda, MD 20892 (Telephone Special Emphasis Panel; Time-Sensitive HUMAN SERVICES
Conference Call). Obesity Research.
Contact Person: Paul A. Rushing, Ph.D., Date: August 8, 2018. National Institutes of Health
Scientific Review Officer, Review Branch, Time: 1:00 p.m. to 3:00 p.m.
DEA, NIDDK, National Institutes of Health, Agenda: To review and evaluate grant National Institute on Drug Abuse;
Room 7345, 6707 Democracy Boulevard, applications. Notice of Closed Meeting
Bethesda, MD 20892–5452, (301) 594–8895, Place: National Institutes of Health, Two
rushingp@extra.niddk.nih.gov. Pursuant to section 10(d) of the
Democracy Plaza, 6707 Democracy
This notice is being published less than 15 Boulevard, Bethesda, MD 20892 (Telephone Federal Advisory Committee Act, as
days prior to the meeting due to the timing Conference Call). amended, notice is hereby given of the
limitations imposed by the review and Contact Person: Michele L. Barnard, Ph.D., following meeting.
funding cycle.
Scientific Review Officer, Review Branch,
Name of Committee: National Institute of The meeting will be closed to the
DEA, NIDDK, National Institutes of Health,
Diabetes and Digestive and Kidney Diseases Room 7353, 6707 Democracy Boulevard,
public in accordance with the
Special Emphasis Panel; Bariatric Surgery-
Bethesda, MD 20892–2542, (301) 594–8898, provisions set forth in sections
Related Applications. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
barnardm@extra.niddk.nih.gov.
Date: July 30, 2018. as amended. The contract proposals and
Time: 2:00 p.m. to 3:00 p.m. Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases the discussions could disclose
Agenda: To review and evaluate grant
applications. Special Emphasis Panel; RFA–DK–17–030 confidential trade secrets or commercial
Place: National Institutes of Health, Two Advancement of Cell Replacement Therapies property such as patentable material,
Democracy Plaza, 6707 Democracy for Type 1 Diabetes (R43/R44). and personal information concerning
Boulevard, Bethesda, MD 20892 (Telephone Date: August 8, 2018. individuals associated with the contract
Conference Call). Time: 12:30 p.m. to 4:30 p.m. proposals, the disclosure of which
Contact Person: Paul A. Rushing, Ph.D., Agenda: To review and evaluate grant would constitute a clearly unwarranted
Scientific Review Officer, Review Branch, applications. invasion of personal privacy.
DEA, NIDDK, National Institutes of Health, Place: National Institutes of Health, Two
Room 7345, 6707 Democracy Boulevard, Democracy Plaza, 6707 Democracy Name of Committee: National Institute on
Bethesda, MD 20892–5452, (301) 594–8895, Boulevard, Bethesda, MD 20892 (Telephone Drug Abuse Special Emphasis Panel, Center
rushingp@extra.niddk.nih.gov. for Genetic Studies (7797).
Conference Call).
This notice is being published less than 15 Contact Person: Ann A. Jerkins, Ph.D., Date: July 25, 2018.
days prior to the meeting due to the timing Scientific Review Officer, Review Branch, Time: 12:00 p.m. to 3:00 p.m.
limitations imposed by the review and DEA, NIDDK, National Institutes of Health, Agenda: To review and evaluate contract
funding cycle. proposals.
Room 7119, 6707 Democracy Boulevard,
Name of Committee: National Institute of Bethesda, MD 20892–5452, 301–594–2242, Place: National Institutes of Health,
Diabetes and Digestive and Kidney Diseases jerkinsa@niddk.nih.gov. Neuroscience Center, 6001 Executive
Special Emphasis Panel; Type 1 Diabetes
Name of Committee: National Institute of Boulevard, Rockville, MD 20852 (Telephone
Small Business Applications.
Date: August 6, 2018. Diabetes and Digestive and Kidney Diseases Conference Call).
Time: 2:00 p.m. to 5:00 p.m. Special Emphasis Panel; NIDDK–R01 Contact Person: Gerald L. McLaughlin,
Agenda: To review and evaluate grant Telephone Review. Ph.D., Scientific Review Officer, Office of
applications. Date: August 10, 2018. Extramural Policy and Review, National
Place: National Institutes of Health, Two Time: 11:00 a.m. to 3:00 p.m. Institute on Drug Abuse, NIH, DHHS, 6001
Democracy Plaza, 6707 Democracy Agenda: To review and evaluate grant Executive Blvd., Room 4238, MSC 9550,
Boulevard, Bethesda, MD 20892 (Telephone applications. Bethesda, MD 20892–9550, 301–827–5819,
Conference Call). Place: National Institutes of Health, Two gm145a@nih.gov.
Contact Person: Ryan G. Morris, Ph.D., Democracy Plaza, 6707 Democracy
Scientific Review Officer, Review Branch, This notice is being published less than 15
Boulevard, Bethesda, MD 20892 (Telephone
DEA, NIDDK, National Institutes of Health, days prior to the meeting due to the timing
Conference Call).
Room 7015, 6707 Democracy Boulevard, limitations imposed by the review and
Contact Person: Xiaodu Guo, MD, Ph.D.,
Bethesda, MD 20892–2542, 301–594–4721, funding cycle.
Scientific Review Officer, Review Branch,
ryan.morris@nih.gov. DEA, NIDDK, National Institutes of Health, (Catalogue of Federal Domestic Assistance
Name of Committee: National Institute of Room 7023, 6707 Democracy Boulevard, Program No.: 93.279, Drug Abuse and
Diabetes and Digestive and Kidney Diseases Bethesda, MD 20892–5452, (301) 594–4719, Addiction Research Programs, National
Special Emphasis Panel; RFA–DK–17–035 guox@extra.niddk.nih.gov. Institutes of Health, HHS)
amozie on DSK3GDR082PROD with NOTICES1
Microphysiological Systems (MPS) for
Modeling Diabetes (UG3/UH3). (Catalogue of Federal Domestic Assistance Dated: July 12, 2018.
Date: August 7, 2018. Program Nos. 93.847, Diabetes,
Natasha M. Copeland,
Time: 11:30 a.m. to 3:30 p.m. Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition Program Analyst, Office of Federal Advisory
Agenda: To review and evaluate
Research; 93.849, Kidney Diseases, Urology Committee Policy.
cooperative agreement applications.
Place: National Institutes of Health, Two and Hematology Research, National Institutes [FR Doc. 2018–15279 Filed 7–17–18; 8:45 am]
Democracy Plaza, 6707 Democracy of Health, HHS) BILLING CODE 4140–01–P
VerDate Sep<11>2014 19:19 Jul 17, 2018 Jkt 244001 PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 E:\FR\FM\18JYN1.SGM 18JYN1](https://thefederalregister.org/doc/83_FR_34080/page/2.svg)
Document Created: 2018-11-06 10:24:35
Document Modified: 2018-11-06 10:24:35
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | July 27, 2018. | |
| FR Citation | 83 FR 33942 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR